Pacgen Life Science Corporation, a life science company, focuses on commercializing biomedical products and services in Canada. It offers lab equipment, including Fit X1 401, an automated high-precision pipetting system designed to replace the manual process of PCR/qPCR sample preparation; electronic pipettes; and A+ Pipette Controller, an electronic pipette controller designed for use with graduated and volumetric glass and plastic pipets, as well as reagent kits. The company’s lead product candidate is PAC-113, a novel antifungal drug that has completed a Phase IIb clinical trial for the treatment of oral candidiasis infections. It has a license agreement with Demegen Inc. to develop and commercialize PAC-113. The company was formerly known as Pacgen Biopharmaceuticals Corporation and changed its name to Pacgen Life Science Corporation in May 2012. The company was founded in 2004 and is headquartered in Vancouver, Canada.
pacgen life science corp (PBS:Venture)
701 West Georgia Street
Vancouver, BC V7Y 1C6
The information and data displayed in this profile are created and managed by Capital IQ, a Standard & Poor's company. Bloomberg.com does not create or control the content.
|No competitor information is available for PBS.|
|View Industry Companies|
|Price/Cash Flow||NM||Not Meaningful|
Sponsored Financial Commentaries
To contact PACGEN LIFE SCIENCE CORP, please visit www.pacgenlife.com. Company data is provided by Capital IQ. Please use this form to report any data issues.